Syndax Pharmaceuticals Inc. (SNDX) Shares Up 3.1%
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)’s share price traded up 3.1% on Tuesday . The stock traded as high as $12.23 and last traded at $12.23, with a volume of 72,944 shares changing hands. The stock had previously closed at $11.86.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 22nd. Morgan Stanley assumed coverage on Syndax Pharmaceuticals in a report on Monday, March 28th. They issued an “overweight” rating and a $22.00 price objective for the company. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, May 17th. JMP Securities assumed coverage on Syndax Pharmaceuticals in a report on Monday, March 28th. They issued an “outperform” rating and a $28.00 price objective for the company. Finally, Citigroup Inc. assumed coverage on Syndax Pharmaceuticals in a report on Monday, March 28th. They issued a “buy” rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $25.00.
The firm’s market cap is $214.10 million. The stock’s 50-day moving average is $11.77 and its 200 day moving average is $13.10.
Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Monday, May 16th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $2.37. Equities research analysts expect that Syndax Pharmaceuticals Inc. will post ($2.93) earnings per share for the current year.
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.